Table 2.
Maternal human immunodeficiency virus (HIV)-related characteristics and prevention of mother-to-child transmission (PMTCT) use, stratified by injecting drug use (IDU) status (n = 6104)
| IDU | Non-IDU | χ2 | |
|---|---|---|---|
| n = 1111 | n = 4993 | P value | |
| n (%) or median (IQR) | |||
| Timing of HIV diagnosis (n = 6200) | |||
| Pre-pregnancy | 524 (47.2) | 1376 (27.6) | 357.9 |
| 1st/2nd trimester | 298 (26.8) | 2674 (53.6) | P < 0.001 |
| 3rd trimester | 173 (15.6) | 790 (15.8) | |
| Intrapartum | 116 (10.4) | 153 (3.1) | |
| WHO clinical stage (n = 5303) | |||
| I or II | 840 (85.7) | 4046 (93.6) | 67.4 |
| III or IV | 140 (14.3) | 277 (6.4) | P < 0.001 |
| CD4 counta (n = 2401) | |||
| <200 cells/mm3 | 52 (14.4) | 163 (7.0) | 19.1 |
| 200–349 cells/mm3 | 80 (22.2) | 439 (21.5) | P < 0.001 |
| 350–499 cells/mm3 | 104 (28.9) | 573 (28.1) | |
| ≥500 cells/mm3 | 124 (34.4) | 866 (42.4) | |
| Median | 428 (267, 588) | 459 (326, 618) | |
| PMTCT prophylaxis—mother | |||
| None | 136 (12.2) | 236 (4.7) | 390.4 |
| sdNVP only | 295 (26.6) | 470 (9.4) | P < 0.001 |
| ZDV and sdNVP | 275 (24.8) | 2232 (44.7) | |
| ZDV | 223 (20.1) | 1158 (23.2) | |
| HAART | 182 (16.4) | 897 (18.0) | |
a
First measurement in pregnancy. IQR: interquartile range; HAART: highly active antiretroviral therapy; sdNVP: single-dose nevirapine; ZDV: zidovudine; WHO: World Health Organization.